Analytical Data
-
Gene name
FLCN
- Application
-
Alternative Names
BHD; FLCL; BHD skin lesion fibrofolliculoma protein; Birt-Hogg-Dube syndrome protein
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8NFG4
-
Expression Region
Arg341~Asn579
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FLCN (Folliculin) is a tumor suppressor protein encoded by the FLCN gene, which has been linked to the development of Birt-Hogg-Dubé syndrome (BHDS), a genetic disorder characterized by skin tumors, lung cysts, and an increased risk of renal cancer. Recent research has highlighted the critical role of FLCN in cellular processes such as energy metabolism, cell proliferation, and DNA damage response. The protein is part of the mTOR signaling pathway, which is essential for cellular growth and homeostasis. Studies have shown that mutations or loss of FLCN function can lead to dysregulation of these pathways, contributing to tumorigenesis. To better understand FLCN's biological functions and mechanisms of action, researchers have focused on the expression and purification of recombinant FLCN protein. This enables the exploration of its structural properties, interactions with other molecular partners, and regulatory roles within the cell. By studying FLCN in a controlled environment, scientists aim to uncover the molecular basis of BHDS and other related disorders, providing insights that could lead to targeted therapies and improved clinical outcomes. The elucidation of FLCN's function is crucial not just for understanding kidney cancer and BHDS, but also for broader applications in cancer biology and treatment strategies.
